• Founded in 2020

MODULAR ANTIBODY-EFFECTOR CELL CONSTRUCTS

Learn more
MODULAR ANTIBODY-EFFECTOR CELL CONSTRUCTS AS THERAPIES FOR ONCOLOGICAL AND AUTOIMMUNE DISEASES

āˆž

Potential drug products created with our technology

2

Common basic substances; effector cells and Fc-engineered ligands

  • our technology

pinā„¢ platform

We develop therapeutic antibody-effector cell constructs by combining Fc-engineered targeting ligands and genetically unmodified effector cells.

Modularity

Our Pinā„¢ Platform enables rapid formulation of antibody-effector cell constructs for identified targets having an available ligand.

Scalability

Our Pinā„¢ Platform facilitates scalable manufacturing through the self-assembly process when ligands and cells are mixed.

Regulatory

Our Pinā„¢ Platform allows for the efficient development and production of diverse drug products with same core drug substances, thereby enabling a simpler regulatory pathway for multiple unique products.

  • Our strategy

Building sustainable value

Pinā„¢ Platform

Unique therapeutic tool combining the power of antibodies and cells.

Pipeline

Lead candidate CYT-102 (anti-EGFR armed NK cells) in glioblastoma (GBM) and other EGFR+ solid tumors.

People

Seasoned management and Board with extensive experience in Big Pharma and early-stage biotech.

Newsroom

  • Press Release
  • Press Release
  • Press Release
  • Press Release
  • Press Release

Innovative products for high unmet needs

  • Support

Our partners

  • Become a partner

INVESTOR OR PARTNER ?

letā€™s talk